Sotera Health Co
In the published model solve dated 2026-Q2, anchored at $19.27, Sotera Health Co (SHC) is priced for +21.1% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 28, 2026 from SEC EDGAR filings.
• Sotera Health runs a regulated, high-switching-cost sterilization and testing oligopoly (Sterigenics, Nordion, Nelson Labs) that earns a roughly 24% operating margin, a moat the $2.16 book value per share badly understates. • The defining risks are leverage and litigation: about $1.92 billion of net debt at 6.7 times operating income, plus ongoing ethylene-oxide tort exposure that drove a $30.9 million settlement charge a year ago. • Watch the deleveraging path and the EO litigation, where Mar
Is SHC overvalued? See what's priced in →
286 institutional managers reported holding SHC in 13F filings for the quarter ended 2026-03-31. 47 opened new positions that quarter. Held by Vanguard Group, Sculptor Capital, BlackRock, among others. On the short side, 17.6M shares were sold short as of the 2026-06-15 count, about 6% of shares outstanding (7.1 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
SHC's share count grew 2.1% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at SHC over the trailing three years. Absence is a fact about the company, not a signal. 36 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
SHC's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-04 | -7.5% | +20.0% |
| 2023-08-04 | -3.7% | -19.0% |
| 2023-11-02 | +1.2% | +25.5% |
| 2024-02-28 | -12.3% | -24.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
SHC's latest 8-K filings: 2026-08-14 (items 5.02); 2026-08-06 (items 2.02, 9.01); 2026-05-22 (items 5.07); 2026-05-20 (items 1.01, 2.03, 9.01); 2026-05-13 (items 1.02, 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 28, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.